Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Arovella Therapeutics (ASX:ALA): ALA-101 Moves Towards First Human Clinical Testing

Arovella Therapeutics Limited (ASX:ALA) is a clinical-stage biotechnology company developing cell therapies for cancer. The company’s lead programme, ALA-101, is an allogeneic cell therapy designed to provide an off-the-shelf treatment approach. This article examines the regulatory progress and clinical pathway for ALA-101.

Sonal Goyal | 18 September 2026

Elixinol Wellness (ASX:EXL): US Business Sale Reshapes Consumer Wellness Strategy

Elixinol Wellness Ltd (ASX:EXL) is an Australian consumer wellness company focused on hemp-based foods, nutrition products and health-related consumer brands. Following the sale of its US business, the company is concentrating on its Australian operations and existing product portfolio. This article examines the strategic …

Sonal Goyal | 18 September 2026

Clarity Pharmaceuticals (ASX:CU6): Copper Supply Network Supports Radiopharmaceutical Development

Clarity Pharmaceuticals Ltd (ASX:CU6) is a Sydney-based radiopharmaceutical company developing targeted cancer imaging and therapy products. The company’s approach combines diagnostic imaging with targeted treatment through theranostic technology. This article examines how copper isotope supply supports the development pathway for its radiopharmaceutical programmes.

Sonal Goyal | 18 September 2026

Medical Developments International (ASX:MVP): Penthrox Growth Supports Business Recovery

Medical Developments International Limited (ASX:MVP) is an Australian healthcare company focused on developing and commercialising medical products, including Penthrox, a portable inhaled pain relief solution. The company’s recent performance has centred on expanding Penthrox adoption across existing markets while improving financial outcomes.

Sonal Goyal | 18 September 2026

IDT Australia (ASX:IDT): Australian Drug Manufacturing Capability Supports Turnaround Strategy

IDT Australia Limited (ASX:IDT) is an Australian pharmaceutical development and manufacturing company focused on supporting the production of medicines and healthcare products. The company provides contract development and manufacturing services across complex pharmaceutical areas, including sterile manufacturing and active pharmaceutical ingredients. This article examines …

Sonal Goyal | 18 September 2026

Mayne Pharma (ASX:MYX): Drug Delivery Expertise Shapes Specialty Pharmaceutical Strategy

Mayne Pharma Group Limited (ASX:MYX) is a specialty pharmaceutical company with operations across Australia and the United States. The company focuses on developing, manufacturing and commercialising pharmaceutical products, with expertise in drug delivery technologies supporting areas including women’s health, dermatology and contract manufacturing.

Sonal Goyal | 18 September 2026

Percheron Therapeutics (ASX:PER): HMBD-002 Licensing Deal Redirects Oncology Strategy

Percheron Therapeutics Limited (ASX:PER) is an Australian biotechnology company focused on developing clinical-stage therapies. The company has transitioned its strategy towards immuno-oncology through HMBD-002, an antibody programme designed to target the VISTA immune checkpoint pathway. This article examines the licensing agreement, development pathway and …

Sonal Goyal | 18 September 2026

Dimerix (ASX:DXB): ACTION3 Kidney Disease Trial Remains Central to Development Path

Dimerix Limited (ASX:DXB) is a Melbourne-based clinical-stage biopharmaceutical company focused on developing therapies for serious medical conditions. Its lead programme, DMX-200, is being investigated for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. This article examines the role of the ACTION3 trial and the …

Sonal Goyal | 18 September 2026

EVE Health Group (ASX:EVE): Men’s Health Expansion Adds a New Direction to Consumer Health Portfolio

EVE Health Group Limited (ASX:EVE) is an Australian consumer health company focused on nutrition, wellness products and health-related consumer solutions. The company has been expanding its strategy beyond traditional wellness products through drug delivery technologies and men’s health applications. This article examines EVE’s evolvingBusinessdirection …

Sonal Goyal | 18 September 2026

Nanosonics (ASX:NAN): CORIS Endoscope Cleaning Platform Expands Infection Control Strategy

Nanosonics Limited (ASX:NAN) is a healthcare technology company focused on infection prevention solutions. The company is known for its trophon high-level disinfection system for ultrasound probes and is expanding its technology portfolio through CORIS, an automated endoscope cleaning platform. This article examines how CORIS …

Sonal Goyal | 18 September 2026
Support

Hi! How can we help you today?

Loading…